MOLN
Molecular PartnersยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
MOLN Profile
Molecular Partners Ag
A Swiss biotech company that develops engineered protein therapy for Covid-19 and cancer
Biological Technology
11/22/2004
06/16/2021
NASDAQ Stock Exchange
159
12-31
Depository Receipts (Ordinary Shares)
Wagistrasse 14, 8952 Zurich-Schlieren, Switzerland
Focus on infectious diseases, oncology and ophthalmology
Molecular Partners AG was incorporated in Switzerland on November 22, 2004. The company is a clinical-stage biopharmaceutical company applying its groundbreaking DARPin product candidates to the treatment of serious diseases, with a current focus on infectious diseases, oncology and ophthalmology. The company's DARPin platform is designed using anchor protein repeats, allowing the company to build product candidates with multiple mechanisms of action to address complex biological problems, while potentially providing patients with products with higher efficacy and fewer adverse events.
